All In Biotech

Drug Trial Radar · NCT00666575

A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Actual Use Study of the Safety and Tolerability of Gabapentin 500 mg in a Potential OTC Population

Last checked: Nov 19, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,105

Planned (sponsor's estimate)

Start

Dec 2004

Primary completion

Not stated

Study completion May 2005

Sponsor

Sponsor type
Industry
First posted
Apr 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety of gabapentin, as compared to placebo, in a potential over-the-counter population with reports of occasional sleeplessness

Conditions

  • Transient Insomnia

Interventions

  • GabapentinDrug

    Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days

  • PlaceboDrug

    Matched placebo oral capsule 30 minutes prior to bedtime for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: Day 45

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Mobile, Alabama

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Beverly Hills, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    Clearwater, Florida

  • Pfizer Investigational Site

    DeLand, Florida

  • Pfizer Investigational Site

    New Port Richey, Florida

  • Pfizer Investigational Site

    Pembroke Pines, Florida

  • Pfizer Investigational Site

    West Palm Beach, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Boise, Idaho

  • Pfizer Investigational Site

    Boise, Idaho

  • Pfizer Investigational Site

    Indianapolis, Indiana

  • Pfizer Investigational Site

    Las Vegas, Nevada

  • Pfizer Investigational Site

    Las Vegas, Nevada

  • Pfizer Investigational Site

    Santa Fe, New Mexico

  • Pfizer Investigational Site

    Nashville, Tennessee

  • Pfizer Investigational Site

    Austin, Texas

  • Pfizer Investigational Site

    Fort Worth, Texas

  • Pfizer Investigational Site

    San Antonio, Texas

  • Pfizer Investigational Site

    San Antonio, Texas

  • Pfizer Investigational Site

    Salt Lake City, Utah

  • Pfizer Investigational Site

    West Jordan, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.